- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00943969
Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass (OBEMO)
December 14, 2015 updated by: Célia LLORET LINARES, Hopital Lariboisière
The bariatric surgery is widely used to treat obesity.
Roux-en-Y gastric bypass is one of the most frequently surgical methods performed and combines restrictive and malabsorptive procedures.
Different data suggest that this surgery may modify drug absorption and we think it would be clinically relevant to describe the consequences of gastric bypass on drug systemic exposure in obese patients, since no data on the comparison between the pharmacokinetics (PK) of a drug before and after surgery are available and help to predict the drugs posology.The investigators decided to study the morphine because there is a lack of information about the PK, pharmacodynamics (PD) et pharmacogenetics (PG) of morphine in obese subjects, in contrary with anaesthetic drugs.
This is a drug with a narrow therapeutic range frequently prescribed in obese patients.
Study Overview
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris cedex 10, France, 75475
- Unit of Therapeutic Research, Department of Internal Medicine, Lariboisière Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged between 18 and 60 years old.
- Patients with morbid obesity (IMC > 40 kg/m²) or severe obesity (IMC=35-40 kg/m²) with co morbidities (sleep apnea syndrome or hypertension or steatosis hepatitis) with a favourable decision of a multidisciplinary team for a gastric bypass.
- Patient agreeing to go 3 times for a one day hospitalisation in the URT of the Lariboisière Hospital for the morphine PK/PD.
- Patient with a previous medical examination.
- Patient giving its well-informed and free consent after information.
Exclusion Criteria:
- diabetes
- concomitant sedative, antidepressive or analgesic treatments or drugs unadvised with morphine
- untreated sleep apnea syndrom, hypoxia (PaO2<70mmHg) or hypercapnia (PaCO2>45mmHg), anaemia <10g/dL, ASAT or ALAT>3N
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: obemo
|
gastric bypass combines restrictive and malabsorptive procedures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
30mg Oral morphine systemic exposure (AUC 0-24)
Time Frame: Before surgery-7-15 days after surgery- 6 months after surgery
|
Before surgery-7-15 days after surgery- 6 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Morphine and M6G AUC, clearance, Cmax and Tmax
Time Frame: Before surgery-7-15 days after surgery- 6 months after surgery
|
Before surgery-7-15 days after surgery- 6 months after surgery
|
fat mass and total body water (assessed by DEXA and BIA)
Time Frame: before surgery and 6 months following surgery
|
before surgery and 6 months following surgery
|
mRNA and protein expression of P-gp , UGT2B7, MRP2 and MRP3 in intestinal biopsies
Time Frame: obtained from the bariatric surgery
|
obtained from the bariatric surgery
|
genetic polymorphisms known to affect expression and/or activity of enzymes, receptors and transporters involved in morphine PK/PD (UGT2B7, P-gp, OPRM1, COMT) and morphine PK/PD
Time Frame: Before surgery
|
Before surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Célia LLoret Linares, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
July 21, 2009
First Submitted That Met QC Criteria
July 21, 2009
First Posted (Estimate)
July 22, 2009
Study Record Updates
Last Update Posted (Estimate)
December 16, 2015
Last Update Submitted That Met QC Criteria
December 14, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPP 0911965
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on gastric bypass
-
Puerta de Hierro University HospitalActive, not recruitingPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Medical University of ViennaUnknown
-
Slotervaart HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownType 2 Diabetes Mellitus | Obesity, MorbidNetherlands
-
Puerta de Hierro University HospitalEnrolling by invitationPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Nemocnice Břeclav, p.o.UnknownDiabetes Mellitus, Type 2 | Obesity, SevereCzech Republic
-
Hospital Universitario Virgen de la ArrixacaUnknownObesity | Diabetes MellitusSpain
-
Kaunas University of MedicineUnknown
-
Ain Shams UniversitySuspended
-
Helsinki University Central HospitalActive, not recruiting
-
University of Roma La SapienzaCompleted